MESO FY 2021 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-76.8% YoY

Gross Profit

-$78M-1049.8% margin

Operating Income

-$109M-1463.2% margin

Net Income

-$99M-1325.3% margin

EPS (Diluted)

$-1.60

Cash Flow

Operating Cash Flow

-$107M

Free Cash Flow

-$108M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$745M

Total Liabilities

$163M

Stockholders' Equity

$581M

Cash & Equivalents

$137M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$32M	-76.8%
Gross Profit	-$78M	-$49M	-58.6%
Operating Income	-$109M	-$75M	-45.7%
Net Income	-$99M	-$78M	-26.8%